Description
Thymosin Alpha-1 is an immune-modulating peptide investigated across infectious-disease, oncology-adjunct, and inflammatory-condition research programs.
What it is
Thymosin Alpha-1 (Talpha1) is an immunomodulatory peptide with broad human-trial literature across infectious, inflammatory, and adjunctive oncology contexts.
Mechanism snapshot
- Modulates innate and adaptive immune-response signaling.
- Investigated for T-cell and cytokine-network effects in disease-specific contexts.
- Used as adjunctive immunologic support in selected clinical programs.
Research programs
- Systematic reviews and meta-analyses across multiple disease states.
- Adjunctive protocol studies in infection and inflammatory indications.
- Safety/tolerability profiling across heterogeneous trial designs.
Limitations
- Evidence quality and design rigor vary across indications.
- Pooling across disease contexts can obscure true effect size.
- Regulatory interpretation differs significantly by region and indication.
Selected references
- Thymosin alpha 1: A comprehensive review of the literature - PubMed 2020
- Comprehensive Review of the Safety and Efficacy of Thymosin Alpha 1 in Human Clinical Trials - PubMed 2024
- Historical review of thymosin alpha 1 in infectious diseases - PubMed 2015
- Thymalfasin (Thymosin Alpha 1) as an Enhancer of Vaccine Response (NCT06821100) - ClinicalTrials.gov Status snapshot
Ordering
Add this item to your cart, submit your shipping details at checkout, and wait for your order confirmation. Interac e-Transfer instructions are sent after the order request is received.


